All articles

Data & Publications Bg

Roginolisib: an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3kδ) in patients with uveal melanoma and advanced cancers

Press Releases Bg

US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy

Data & Publications Bg

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition

Data & Publications Bg

Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nabpaclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

Data & Publications Bg

Preclinical activity of novel TGF beta receptor I kinase Inhibitors IOA-359 and IOA-360 for treatment of anemia in MDS/AML

Data & Publications Bg

Novel PI3Kδ inhibitor roginolisib synergizes with the Bcl-2 inhibitor venetoclax in hematological malignancies

Press Releases Bg

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO immuno-oncology congress 2023

Data & Publications Bg

Safety and clinical efficacy of roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase Inhibitor delta (PI3Kδ)

Press Coverage Bg

pharmaphorum — Uveal melanoma: a new generation of therapies offers hope for patients

Press Coverage Bg

Immuno-Oncology Insights — Navigating the complexities of immunotherapy: unraveling novel targets & pathways

Press Coverage Bg

Drug Target Review — Combining autotaxin and TGF-β inhibitors in cancer

Press Releases Bg

iOnctura to present research on roginolisib and IOA-359 at ASH

Hero Bg

Looking for media
resources?

iOnctura
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.